

IN THE SPECIFICATION:

Page 1, line 1, before "BACKGROUND OF THE INVENTION,"
insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

B1
This application is a division of application Serial No. 07/832,871, filed February 10, 1992, which is a division of application Serial No. 07/158,073, filed February 12, 1988, now allowed, which is a continuation of application Serial No. 06/914,156, filed October 1, 1986, now abandoned, which is a continuation of application Serial No. 06/706,562, filed February 22, 1985, now abandoned, which is a continuation-in-part of application Serial No. 06/558,109, filed December 5, 1983, now abandoned, which are incorporated by reference herein.--

line 8, delete the comma.

Page 2, line 13, delete "Gallo" and insert therefor
--Guroff---;

line 14, after "Med." insert --154:1957-64--;
and after "al" insert a period;

line 16, after "77" insert --:7415-19--; and
change "Barre-Sinousi" to --Barre-Sinoussi--;

line 17, change "Gellman" to --Gelman--;

line 18, delete "Ibid.";

line 19, change "all" to --al---;

line 20, change "Barre-Sinousi" to --Barre-Sinoussi et al.--;

LAW OFFICES

FINNEGAN, HENDERSON
FARABOW, GARRETT
& DUNNER

1300 I STREET, N. W.
WASHINGTON, DC 20005
1-202-408-4000

line 21, change "Ray" to --Rey--; and

line 26, change "reference" to --references--.

Page 3, delete lines 1-24;

line 25, change "syndrom" to --syndrome--; and

line 34, after "indirectly" insert a comma.

Page 4, line 13, delete the comma after
"administration"; and

line 36, delete "of" (second occurrence) and
insert therefor --from--.

Page 5, line 1, change "et al." to --et al., Science
218:571-3--;

line 27, change "<interferon" to --α-
interferon--;

line 32, after ")" insert --)---;

line 33, change "t" to --to--; and

line 37, change "Barre-Sinousi" to --Barre-
Sinoussi--.

Page 6, line 7, delete "B.J."; and change "et al." to
--et al.---;

line 8, change "77, 7415" to --77:7415--;

line 11, change "on" to --in--;

line 14, change "concultivation" to
--cocultivation--; and

between lines 16 and 17, insert:

--SUMMARY OF THE INVENTION--.

LAW OFFICES

FINNEGAN, HENDERSON
FARABOW, GARRETT
& DUNNER

1300 I STREET, N. W.
WASHINGTON, DC 20005
1-202-408-4000

Page 6, line 20, change "and being" to --which--;
line 26, change "of" to --to--;
line 30, delete the comma and insert therefor
--and--; delete "however"; and after "be" (second occurrence)
insert --initially--;

line 31, delete "first"; and
between lines 31 and 32 insert:

--BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is an electron micrograph of ultrathin sections
of lymphocytes of a healthy adult donor infected with the
retrovirus isolated from a haemophiliac patient with AIDS
(IDAV2).

Fig. 2 is an ultrastructural comparison between HTLV and
LAV.

Fig. 3 is an intracellular vesicle in LAV-infected
lymphocytes.

Fig. 4 is an electrophoresis and autoradiogram of
³⁵methionine-labelled LAV.

Fig. 5 is a polyacrylamide (12.5%) electrophoresis gel
of immune complexes between ³⁵S-labelled virus and horse sera.

DETAILED DESCRIPTION--.

Page 6, line 33, after "Particularly" insert a comma;
line 35, change "establised" to --established--;
line 36, change "Institute" to --Institut--; and
line 37, change "co-cultivate" to
--cocultivated--.

Page 7, line 17, change "show" to --showed--.

Page 8, line 1, change "on" to --in--;

line 2, after "described" insert --by Barre-Sinoussi et al.--; and change "1983, vol. 220, pages 868-870" to --220:868-70 (1983)--;

line 12, change "dependant" to --dependent--;

line 32, change "s" to --as--; and

line 34, change "deoxythymodylate" to --deoxythymidylate--.

Page 9, line 2, change "particules" to --particles--;

line 23, after "contrast" insert a comma;

line 36, change "et al." to --et al.--; and

line 37, change "154, 1957" to --154:1957-64--;

Page 10, line 1, delete "V.S."; delete "et al." and insert --et al.--; and delete "38, 906" and insert --38:906-915--;

line 9, change "219, 856" to --219:856-859--;

line 13, change "cord" to --Cord--; and

line 27, after "Conversely" insert a comma.

Page 11, line 12, change "bracketed" to --parenthetical--;

line 33, change "be" to --by--; and

line 35, after "example" insert a comma.

Page 12, line 3, after "Therefore" insert a comma;
line 8, after "manner" insert a comma;
line 17, delete "R.C.";
line 18, change "et al" to --et al.--;
line 35, change "method" to --methods--; and
line 36, after "for" (second occurrence) insert
--determining--.

Page 13, line 17, after "respect" insert a comma; and
line 26, after "IDAV2" insert a comma;

Page 14, line 18, after "Thus" insert a comma;
line 29, change "immunoglobulines" to
--immunoglobulins--; and

line 34, after "and" insert a semicolon.

Page 15, line 7, after "proteins" insert a comma;
line 18, after "methods" insert a comma;
line 29, after "is" insert a comma; after
"however" insert a comma;

line 32, change "which" to --who--;

line 33, change "repeatedly" to --repeatedly--;

Page 16, line 9, change 5.10^6 to $--5 \times 10^6--$;

line 13, change 2.10^6 to $--2 \times 10^6--$;

line 15, change "centriguged" to
--centrifuged--;

line 24, change "aerum" to --serum--;

line 26, after "anti-human" insert -- α --;

line 32, change "cases" to --case was--; and
line 33, delete "was".

Page 17, line 3, change "Polyethylenglycol" to
--polyethyleneglycol--;

line 7, after "in" insert --an--; and change
"radio-immune" to --radioimmune--;

line 14, change "except" to --with--;

line 26, change "preferred" to --Preferred--;

and

line 30, change "peroxydase" to --peroxidase--.

Page 18, line 3, delete "is used"; and

line 12, change "detecting" to --detection--.

Page 19, line 3, after "taken" insert --up--;

line 7, change "ten" to --then--;

line 23, after "0.2 M" insert --)--;

line 24, after "0.2 M" insert --)--;

line 25, change "foetal" to --fetal--;

line 27, change "albumine" to --albumin--; and

line 28, change "peroxydase" to --peroxidase--.

Page 20, line 2, change "albumine" to --albumin--;

line 3, after "ml" insert a period;

line 6, change "albumine" to --albumin--;

line 9, delete the comma (first occurrence);

before "2H₂O" insert a period (centered in the middle of the
line);

line 10, delete the comma (first occurrence);
before "1H₂O" insert a period (centered in the middle of the
line);

line 11, change "peroxyde" to --peroxide--;

line 22, change "(marked)" to --(marked)--;

line 26, change "(marked)" to --(marked)--;

and

line 32, change "peroxydase" to --peroxidase--.

Page 21, line 2, change "of" to --from--;

line 9, change "foetal" to --fetal--;

line 23, change "albumine" to --albumin--;

line 29, change "equiped" to --equipped--; and

line 32, change "peroxydase" to --peroxidase--.

Page 22, line 12, change "a" to --an--;

line 14, after "equal" insert --to--; and

change "to" (last occurrence) to --than--;

line 16, change "eitehr" to --either--; and

line 35, change "12,5" to --12.5--.

Page 24, line 13 from the bottom, change "serveral" to
--several--.

Page 25, line 3, after "Particularly" insert a comma;

line 18, change "unfrequent" to --infrequent--;

line 22, change "person" to --persons--;

LAW OFFICES

FINNEGAN, HENDERSON
FARABOW, GARRETT
& DUNNER

1300 I STREET, N. W.
WASHINGTON, DC 20005
1-202-408-4000

line 26, change "as" to --whether or not--; and
delete "had" (second occurrence); and

line 27, delete "or not".

Page 26, line 21, change "of" (second occurrence) to
--or--.

Page 27, line 6, after "(C.N.C.M.)" insert a comma and
--Institut Pasteur, 28 Rue du Docteur Roux, 75724 Paris Cedex
15,--.

IN THE CLAIMS:

Please cancel claim 1, without prejudice, and add the
following claims.

~~Sub. 15~~
Sub. 15. An isolated and purified antibody which binds with
a protein of human immunodeficiency virus type 1 (HIV-1),
wherein said protein is p12 protein of HIV-1.

~~Sub. 16~~
Sub. 16. An isolated and purified antibody which binds with
a protein of human immunodeficiency virus type 1 (HIV-1),
wherein said protein is p18 protein of HIV-1.

~~Sub. 17~~
Sub. 17. The antibody according to claim 15 or 16, wherein
the antibody is labeled with a label selected from the group
consisting of a radioactive label, an enzymatic label, a
fluorescent label, a chemiluminescent label, and a
chromophore label.

~~Sub. 18~~
Sub. 18. An isolated and purified mixture of antibodies
which bind with proteins of human immunodeficiency virus type
1 (HIV-1), wherein said proteins are p12 and p25 proteins of
HIV-1.